F resenius Kabi has entered a global licensing agreement for the commercialisation of Polpharma Biologics’s vedolizumab ...

AMSTERDAM, ZUG, Switzerland & GDAŃSK, Poland, August 05, 2025--Polpharma Biologics S.A. ("Polpharma Biologics") announces a ...

The efficacy of currently licensed biologics for treatment of ulcerative colitis: a literature review. Cureus. 2023 Apr 15;15 (4):e37609. doi: 10.7759/cureus.37609. PMID: 37069838; PMCID: PMC10105519.

Entyvio (generic name vedolizumab) is now available as a self-administered injection for cases of moderately-to-severely ...

VANCOUVER, British Columbia, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a unique platform of immunotherapies ...

A new study finds biologic use during pregnancy varies by autoimmune condition, with higher use in Crohn’s and lower use in psoriasis and arthritis.

A study published in Gut found that biologic therapies were ineffective in treating inflammatory bowel disease. Canadian researchers studied how infliximab affected Crohn’s disease patients from ...

Medicine New drug for IBD, ulcerative colitis wins FDA approval: ‘Amazing results’ By Marc Lallanilla Published Oct. 16, 2023, 4:24 p.m. ET ...

In a smaller cohort of 43 patients genetically pretested for likely response to the new biologic, remission after treatment was only slightly higher at 32% vs 11% (95% CI, 2-38, P = .02).

Key Takeaways Oral small-molecule therapies are redefining first-line treatment in moderate to severe ulcerative colitis (UC) by offering noninfusion alternatives with rapid onset and high ...

TAKEAWAY: Among 11,992 adult patients newly initiating biologic therapy (median age, 47 years; 52.7% women), 1293 (10.8%) underwent a biologic switch during a minimum follow-up of 90 days.

Polpharma Biologics & Fresenius Kabi enter licensing agreement for proposed vedolizumab biosimilar, PB016: Amsterdam Wednesday, August 6, 2025, 11:00 Hrs [IST] Polpharma Biologics ...